Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Retained Earnings (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Retained Earnings for 11 consecutive years, with -$171.8 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings changed N/A to -$171.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$171.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$171.8 million for FY2025, N/A changed from the prior year.
  • Retained Earnings for Q4 2025 was -$171.8 million at Crescent Biopharma, down from -$79.4 million in the prior quarter.
  • The five-year high for Retained Earnings was -$54.8 million in Q2 2025, with the low at -$496.7 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$369.2 million, with a median of -$409.3 million recorded in 2022.
  • The sharpest move saw Retained Earnings dropped 21.66% in 2021, then skyrocketed 88.52% in 2025.
  • Over 5 years, Retained Earnings stood at -$372.9 million in 2021, then decreased by 12.52% to -$419.6 million in 2022, then decreased by 8.79% to -$456.5 million in 2023, then decreased by 6.72% to -$487.1 million in 2024, then skyrocketed by 64.73% to -$171.8 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$171.8 million, -$79.4 million, and -$54.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.